vs
Globalstar, Inc.（GSAT）与MESA LABORATORIES INC（MLAB）财务数据对比。点击上方公司名可切换其他公司
Globalstar, Inc.的季度营收约是MESA LABORATORIES INC的1.1倍（$72.0M vs $65.1M），MESA LABORATORIES INC净利率更高（5.6% vs -16.1%，领先21.7%），Globalstar, Inc.同比增速更快（17.6% vs 3.6%），过去两年Globalstar, Inc.的营收复合增速更高（12.9% vs 5.1%）
Globalstar Inc.是一家美国电信企业，运营近地轨道卫星星座，可提供卫星电话、低速数据传输及对地观测服务，其第二代卫星星座由25颗卫星组成，相关服务可覆盖全球大部分区域的通信及遥感需求。
梅萨实验室有限公司开发、生产和销售专业质控、校准及监测仪器与配套服务，核心业务覆盖医疗健康、制药、食品饮料、工业卫生及环境检测领域，为全球客户满足合规及运营安全需求提供支持。
GSAT vs MLAB — 直观对比
营收规模更大
GSAT
是对方的1.1倍
$65.1M
营收增速更快
GSAT
高出14.0%
3.6%
净利率更高
MLAB
高出21.7%
-16.1%
两年增速更快
GSAT
近两年复合增速
5.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $72.0M | $65.1M |
| 净利润 | $-11.6M | $3.6M |
| 毛利率 | — | 64.2% |
| 营业利润率 | -0.5% | 12.2% |
| 净利率 | -16.1% | 5.6% |
| 营收同比 | 17.6% | 3.6% |
| 净利润同比 | 76.9% | 316.6% |
| 每股收益（稀释后） | $-0.11 | $0.65 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GSATMLAB
| Q4 25 | $72.0M | $65.1M | ||
| Q3 25 | $73.8M | $60.7M | ||
| Q2 25 | $67.1M | $59.5M | ||
| Q1 25 | $60.0M | $62.1M | ||
| Q4 24 | $61.2M | $62.8M | ||
| Q3 24 | $72.3M | $57.8M | ||
| Q2 24 | $60.4M | $58.2M | ||
| Q1 24 | $56.5M | $58.9M |
净利润GSATMLAB
| Q4 25 | $-11.6M | $3.6M | ||
| Q3 25 | $1.1M | $2.5M | ||
| Q2 25 | $19.2M | $4.7M | ||
| Q1 25 | $-17.3M | $-7.1M | ||
| Q4 24 | $-50.2M | $-1.7M | ||
| Q3 24 | $9.9M | $3.4M | ||
| Q2 24 | $-9.7M | $3.4M | ||
| Q1 24 | $-13.2M | $-254.6M |
毛利率GSATMLAB
| Q4 25 | — | 64.2% | ||
| Q3 25 | — | 61.5% | ||
| Q2 25 | — | 62.0% | ||
| Q1 25 | — | 61.8% | ||
| Q4 24 | — | 63.3% | ||
| Q3 24 | — | 61.3% | ||
| Q2 24 | — | 64.0% | ||
| Q1 24 | — | 62.1% |
营业利润率GSATMLAB
| Q4 25 | -0.5% | 12.2% | ||
| Q3 25 | 13.8% | 7.8% | ||
| Q2 25 | 9.2% | 5.1% | ||
| Q1 25 | -14.2% | 2.4% | ||
| Q4 24 | -6.9% | 9.2% | ||
| Q3 24 | 13.0% | 6.1% | ||
| Q2 24 | -2.4% | 9.6% | ||
| Q1 24 | -8.3% | -460.6% |
净利率GSATMLAB
| Q4 25 | -16.1% | 5.6% | ||
| Q3 25 | 1.5% | 4.1% | ||
| Q2 25 | 28.6% | 8.0% | ||
| Q1 25 | -28.9% | -11.4% | ||
| Q4 24 | -82.1% | -2.7% | ||
| Q3 24 | 13.7% | 5.9% | ||
| Q2 24 | -16.0% | 5.8% | ||
| Q1 24 | -23.4% | -432.2% |
每股收益（稀释后）GSATMLAB
| Q4 25 | $-0.11 | $0.65 | ||
| Q3 25 | $-0.01 | $0.45 | ||
| Q2 25 | $0.13 | $0.85 | ||
| Q1 25 | $-0.16 | $-1.30 | ||
| Q4 24 | $-0.57 | $-0.31 | ||
| Q3 24 | $0.00 | $0.63 | ||
| Q2 24 | $-0.01 | $0.62 | ||
| Q1 24 | $-0.01 | $-47.26 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $447.5M | $29.0M |
| 总债务越低越好 | $483.8M | $68.4M |
| 股东权益账面价值 | $355.7M | $186.7M |
| 总资产 | $2.3B | $434.8M |
| 负债/权益比越低杠杆越低 | 1.36× | 0.37× |
8季度趋势，按日历期对齐
现金及短期投资GSATMLAB
| Q4 25 | $447.5M | $29.0M | ||
| Q3 25 | $346.3M | $20.4M | ||
| Q2 25 | $308.2M | $21.3M | ||
| Q1 25 | $241.4M | $27.3M | ||
| Q4 24 | $391.2M | $27.3M | ||
| Q3 24 | $51.9M | $24.3M | ||
| Q2 24 | $64.3M | $28.5M | ||
| Q1 24 | $59.3M | $28.2M |
总债务GSATMLAB
| Q4 25 | $483.8M | $68.4M | ||
| Q3 25 | $508.6M | $69.4M | ||
| Q2 25 | $491.5M | $70.3M | ||
| Q1 25 | $502.7M | $71.3M | ||
| Q4 24 | $511.4M | $72.2M | ||
| Q3 24 | $394.4M | $73.1M | ||
| Q2 24 | $393.1M | $74.1M | ||
| Q1 24 | $398.7M | — |
股东权益GSATMLAB
| Q4 25 | $355.7M | $186.7M | ||
| Q3 25 | $364.8M | $178.5M | ||
| Q2 25 | $360.9M | $172.5M | ||
| Q1 25 | $344.3M | $159.8M | ||
| Q4 24 | $358.9M | $155.2M | ||
| Q3 24 | $394.1M | $161.5M | ||
| Q2 24 | $383.0M | $150.7M | ||
| Q1 24 | $377.1M | $145.4M |
总资产GSATMLAB
| Q4 25 | $2.3B | $434.8M | ||
| Q3 25 | $2.2B | $430.4M | ||
| Q2 25 | $1.9B | $435.7M | ||
| Q1 25 | $1.7B | $433.3M | ||
| Q4 24 | $1.7B | $433.3M | ||
| Q3 24 | $917.6M | $454.1M | ||
| Q2 24 | $926.2M | $440.4M | ||
| Q1 24 | $917.0M | $446.8M |
负债/权益比GSATMLAB
| Q4 25 | 1.36× | 0.37× | ||
| Q3 25 | 1.39× | 0.39× | ||
| Q2 25 | 1.36× | 0.41× | ||
| Q1 25 | 1.46× | 0.45× | ||
| Q4 24 | 1.43× | 0.47× | ||
| Q3 24 | 1.00× | 0.45× | ||
| Q2 24 | 1.03× | 0.49× | ||
| Q1 24 | 1.06× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $175.9M | $18.8M |
| 自由现金流经营现金流 - 资本支出 | — | $18.0M |
| 自由现金流率自由现金流/营收 | — | 27.7% |
| 资本支出强度资本支出/营收 | — | 1.1% |
| 现金转化率经营现金流/净利润 | — | 5.17× |
| 过去12个月自由现金流最近4个季度 | — | $37.9M |
8季度趋势，按日历期对齐
经营现金流GSATMLAB
| Q4 25 | $175.9M | $18.8M | ||
| Q3 25 | $236.0M | $8.2M | ||
| Q2 25 | $157.9M | $1.9M | ||
| Q1 25 | $51.9M | $12.7M | ||
| Q4 24 | $340.7M | $18.1M | ||
| Q3 24 | $32.0M | $5.3M | ||
| Q2 24 | $36.7M | $10.7M | ||
| Q1 24 | $29.8M | $12.9M |
自由现金流GSATMLAB
| Q4 25 | — | $18.0M | ||
| Q3 25 | — | $7.1M | ||
| Q2 25 | — | $884.0K | ||
| Q1 25 | — | $11.9M | ||
| Q4 24 | — | $17.3M | ||
| Q3 24 | — | $3.5M | ||
| Q2 24 | — | $9.9M | ||
| Q1 24 | — | $12.3M |
自由现金流率GSATMLAB
| Q4 25 | — | 27.7% | ||
| Q3 25 | — | 11.7% | ||
| Q2 25 | — | 1.5% | ||
| Q1 25 | — | 19.2% | ||
| Q4 24 | — | 27.6% | ||
| Q3 24 | — | 6.0% | ||
| Q2 24 | — | 16.9% | ||
| Q1 24 | — | 21.0% |
资本支出强度GSATMLAB
| Q4 25 | — | 1.1% | ||
| Q3 25 | — | 1.8% | ||
| Q2 25 | — | 1.7% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 1.3% | ||
| Q3 24 | — | 3.1% | ||
| Q2 24 | — | 1.5% | ||
| Q1 24 | — | 0.9% |
现金转化率GSATMLAB
| Q4 25 | — | 5.17× | ||
| Q3 25 | 216.53× | 3.32× | ||
| Q2 25 | 8.22× | 0.40× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.23× | 1.54× | ||
| Q2 24 | — | 3.17× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
GSAT
| Services | $67.4M | 94% |
| Products | $4.6M | 6% |
MLAB
| Sterilization And Disinfection Control | $24.9M | 38% |
| Biopharmaceutical Development | $14.4M | 22% |
| Other | $14.1M | 22% |
| Clinical Genomics | $11.8M | 18% |
